专利检索 ap:("Sandoz AG") AND inv:"Erwin Paul Schreiner" 第 1 页

1.

发明授权
Crystalline forms of cabozantinib phosphate and cabozantinib hydrochloride 有权

公开(公告)号：US10053427B2

公开(公告)日：2018-08-21

申请号：US15560527

申请日：2016-03-22

申请人： Sandoz AG

发明人： Marijan Stefinovic , Erwin Paul Schreiner

IPC分类号： C07D215/233 , A61K31/47 , A61P35/00

CPC分类号： C07D215/233 , A61P35/00 , C07B2200/13 , C07D215/22

摘要： The present invention relates to crystalline forms of cabozantinib phosphoric acid salt and cabozantinib hydrochloric acid salt and to a method for their preparation. Furthermore, the invention relates to pharmaceutical compositions comprising said crystalline forms and their use as anti-cancer medicaments. Cabozantinib, i.e. N-{4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl}-N′-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide is represented by the chemical structure: Formula.

2.

发明授权
Cabozantinib salts and their use as anti-cancer agents 有权

公开(公告)号：US10206916B2

公开(公告)日：2019-02-19

申请号：US15560519

申请日：2016-03-22

申请人： Sandoz AG

发明人： Marijan Stefinovic , Erwin Paul Schreiner

IPC分类号： A61K31/47 , A61P35/00 , C07D215/20 , C07D215/22

摘要： The present invention relates to crystalline forms of cabozantinib succinate (Form A) and cabozantinib acetate (Form A-1) and to pharmaceutical compositions comprising said crystalline forms and their use as anti-cancer medicaments.